2019 Spring ADRC Meeting

Biomarkers Special Emphasis Session

Introduction to FDA's role in regulation of Alzheimer's diagnostic tests
Doug Jeffery, PhD, Acting Deputy Division Director, Division of Immunology and Hematology Devices, Center for Devices and Radiological Health, U.S. Food & Drug Administration
Advances in clinical mass spectrometry and AD biomarker discovery
Conformational proteomics (presentation unavailable)
John Yates III, PhD, Professor, Department of Molecular Medicine, Scripps Research, San Diego, CA
New proteomics strategies for studying Alzheimer's and related dementias
Michael MacCoss, PhD, Professor of Genome Sciences, University of Washington
Using targeted proteomic assays in the care of patients
Andy Hoofnagle, MD, PhD, Professor, Department of Laboratory Medicine, University of Washington
Start right in order to end right (presentation unavailable)
Rebecca Van Eyk, PhD, Professor, Department of Biomedical Sciences, Cedars-Sinai, Los Angeles, CA
AMP-AD pilot biomarker discovery projects
Laurie Ryan, PhD, Program Director, Chief, Dementias of Aging Branch, Division of Neuroscience, NIA/NIH
Exploring the transcriptome for novel biomarker discovery
Nilufer Ertekin-Taner, MD, PhD, Professor of Neuroscience and Neurology, Mayo Clinic, Jacksonville, FL
Integrative proteomics for biomarker discovery in AD
Nicholas Seyfried, PhD, Associate Profressor, Department of Biochemistry, Emory University, Atlanta, GA
Targeted metabolomics of targeted and central mediators: Searching for peripheral biomarkers of central effects
John Newman, PhD, Research Chemist, USDA, ARS, Western Human Nutrition Research Center, Davis, CA

Administrators Meeting

Mary Sundsmo: Celebration of Life
Participant burden
Jennifer Lingler, PhD, ORE Core Leader, University of Pennsylvania
Research registries
Eric Reiman, MD, Director, Arizona ADRC
The language of consents
Kelley Faber, MD, CCRC, Manager, National Cell Repository for Alzheimer's Disease
Return of results
Neelum Aggarwal, MD, Clinical Core Leader, Rush University
Data and specimen sharing
John Gibbons, MS, Data Manager, Rush University
Tatiana Foroud, PhD, PI, National Cell Repository for Alzheimer's Disease

Directors Meeting

Directors Meeting presentation
NIA updates
Eliezer Masliah, MD, Director, Division of Neuroscience, NIA/NIH
NIA updates
Nina Silverberg, PhD, Director, ADRC Program, NIA/NIH
NIA/OCPL update
Joe Balintfy, Sr. Public Affairs Specialist, Alzheimer's and Related Dementias, NIA Office of Communications and Public Liaison, NIA/NIH
Report from the ADRD Summit
Julie Schneider, MD, MS, Scientific Chair, ADRD Summit; NP Core Leader, Rush University ADRC
Update of biomarkers and current status
Planning for fluid biomarkers on a larger scale
Tatiana Foroud, PhD, PI, National Cell Repositofy for Alzheimer's Disease
Updates from the Alzheimer's Association Standardization of Blood Biomarkers Preanalytical Protocol Workgroup
Rebecca Edelmeyer, PhD, Alzheimer's Association

Clinical Core Leaders Meeting

Vascular contributions to cognitive impairment: Are we ready for a "V" in the ATN framework?
Welcome and overview of session
Cindy Carlsson, MD, MS, Chair, ADRC Clinical Core Leaders Steering Committee, Clinical Core Leader, University of Wisconsin
Biomarker Disclosure Workgroup, Research/Analysis Subcommittee: Framework for informing disclosure
Deborah Blacker, MD, ScD, Clinical Core Leader, REC Leader, Massachusetts ADRC